Author Claim Review

 Quick Explanation Copied

 Long Explanation

Citation Metrics and Career Profile

OpenAlex records for Gilad Bachrach (ORCID 0000-0003-1350-2280) show 90 works, ~6,370 citations, and an h-index of 33, with citation output accelerating sharply after 2015 (e.g., 72 citations in 2012 rising to 496 in 2021, 681 in 2022, and ~972 in 2025). This trajectory tracks the impact of the Fusobacterium nucleatum–cancer program carried out with collaborators at the Hebrew University of Jerusalem, notably Ofer Mandelboim.

The top-cited works demonstrate genuine field-defining contributions: the Fap2–TIGIT paper (Immunity 2015, ~1,485 citations), Fap2–Gal-GalNAc colorectal enrichment (Cell Host & Microbe 2016, ~887), breast cancer colonization (Nature Communications 2020, ~715), and a Periodontology 2000 review (2022, ~195) Fap2-TIGIT landmark paper Fap2 Gal-GalNAc colonization paper.

Scrutiny of the Supplied Claim-Level Evidence

The 2008 AAC paper on Porphyromonas gingivalis antimicrobial peptide resistance reflects solid, controlled in vitro work (triplicate, three independent experiments, protease-deficient KDP136 mutant, D-enantiomer controls, fluorescent binding assays) concluding protease-independent resistance via low peptide affinity, with MIC of LL-37 for KDP136 exceeding 200 µg/ml. BGPT extraction scored it 7/10 on scientific quality and reproducibility, with limitations noted around in vitro relevance and unquantified MIC data P. gingivalis peptide resistance study. By contrast, the 2026 eLife RadD–NKp46 paper scored lower (quality 4, reproducibility 3): it lacks a direct purified RadD–NKp46 binding assay, some in vivo tumor-growth results appear internally contradictory (RadD presence correlating with increased tumor burden in WT mice), and the TCGA/TCMA survival associations are correlative with tumor-type specificity (HNSC HR 2.08, 95% CI 1.20–3.61; CRC HR 0.71, CI 0.26–1.95) RadD-NKp46 eLife study. Note also a discrepancy between the narrow Semantic Scholar slice (h-index 2, 20 citations, 4 papers) and the full OpenAlex profile (h-index 33) — the latter better reflects his career given obvious author-disambiguation artifacts in the former.

Blindspots and What Would Change the Verdict

Known: mechanistic impact in the F. nucleatum–tumor immunology niche is real and heavily cited. Inferred: his late-career papers may be riding co-author networks (Mandelboim group) rather than first/last-author leadership — the listed recent papers include conference abstracts (ASCO 1418P), which dilute the recent record. Uncertain: whether the RadD–NKp46 axis survives direct purified-binding tests; falsification would require SPR/ELISA with purified components or multi-model in vivo independence of NK control from RadD status RadD-NKp46 falsification criteria. Potential publication bias toward NK-activating over inhibitory (Siglec-7) interactions is flagged within the study commentary itself.

 BGPT Author Review

Scientific Quality

Genuine field-shaping contributions (Fap2-TIGIT, Gal-GalNAc tumor tropism, breast cancer colonization) with 6,370+ citations and h-index 33 indicate real mechanistic impact. However, the recent RadD-NKp46 work shows reproducibility weaknesses (no direct purified binding assay, contradictory in vivo data), and some recent outputs are conference abstracts. High impact, uneven late-stage rigor.

Communication Quality

Publishes in top-tier journals (Immunity, Cell Host & Microbe, Nature Communications, eLife) with clearly framed mechanistic hypotheses; the Periodontology 2000 review demonstrates synthesis ability. Deductions for internal contradictions in the RadD narrative and incomplete quantification in earlier work.

Author Novelty

His group pioneered the mechanistic basis of intratumoral Fusobacterium-host immune interactions (TIGIT binding, Gal-GalNAc targeting, circulatory seeding hypothesis), opening a now-large subfield; recent NKp46-RadD work extends but is less certain.

Scientific Rigor

Earlier work (2008 AAC) is well-controlled and reproducible (scored 7). The 2026 eLife paper scores 4 on rigor/reproducibility: missing direct binding evidence, correlative clinical claims with wide CIs, in vivo contradictions, and a breast cancer model used to generalize toward HNSC.